Post Profile






NYU's Bluestone Center Awarded $1.2M from NIH to Investigate Gene Delivery for the Treatment of Oral Cancer Pain

Gene therapy is emerging as an exciting alternative to opioids for the treatment of cancer pain. The NYU researchers seek to alleviate oral cancer pain by reversing epigenetic changes, and using gene therapy, set the stage for a new class of medicines that selectively disrupt nociceptive signaling with fewer off-target effects.
read more

share

Related Posts


$4.5 Million For Breast Cancer Research Awarded To NYU Langone Medical Center

Health : Medical News Today

NYU Langone Medical Center has announced that the U.S. Department of Defense (DOD) Breast Cancer Research Program (BCRP) of the Office of the Congressionally Directed Medical Research Programs has awarded Silvia Formenti, MD, the Sa...

More Than $30 Million In Stimulus Funds Received By NYU Langone Medical Center Researchers

Health : Medical News Today

NYU Langone Medical Center has been awarded more than $30 million in research grants from the National Institute of Health (NIH) for 86 research projects being conducted at NYU School of Medicine across a broad range of basic scienc...

NYU Bluestone Center's Yi Ye Awarded a 2015 Early Career Research Grant from the International Association for the Study of Pain

Health : Newswise Medical News

Yi Ye, MS, PhD, associate director, Clinical Research Operations at NYU's Bluestone Center for Clinical Research at the NYU College of Dentistry was selected for the International Association for the Study of Pain's (IASP) 2015 Earl...

NYU's Bluestone Center Receives a $369,250 High Priority, Short-Term Project Award from NIDCR to Study Oral Cancer Pain

Health : Newswise Medical News

The proposed studies are designed to test whether nonviral gene delivery into the oral cancer could be used to treat cancer pain effectively and safely.

NYU's Bluestone Center for Clinical Research and UCLA Awarded $2.4M from NIH to Further Study the Use of Non-Psychotropic Cannabinoids to Suppress Chronic Cancer Pain

Health : Newswise Medical News

The purpose of the five-year, $2,494,784 R01 grant from the National Institutes of Health National Cancer Institute (NIH/NCI) is to test PRCBs for oral cancer and chemotherapy-induced peripheral neuropathy pain reduction.

Comments


Copyright © 2016 Regator, LLC